Gilgamesh Pharma

Gilgamesh Pharma (Gilgamesh Pharmaceuticals, Inc.) is a New York based clinical-stage neuroscience company founded in 2019 that develops rapid-acting, next-generation therapeutics for psychiatric and substance use disorders. Its discovery and translational platform combines medicinal chemistry, neurocircuitry science, electrophysiology and machine learning to identify new chemical entities, and its pipeline spans short-acting 5-HT2A receptor agonists, NMDA receptor antagonists, non-hallucinogenic neuroplastogens, cardiac-safe ibogaine analogs and M1/M4 muscarinic programs. Lead assets include bretisilocin (GM-2505), acquired by AbbVie in August 2025, and blixeprodil (GM-1020), an orally bioavailable NMDAR antagonist in Phase 2 for major depressive disorder. Gilgamesh is a drug developer, not a software vendor: it publishes no developer program, public API, SDK or machine-readable specification of any kind.

Gilgamesh Pharma is profiled on the APIs.io network. Tagged areas include Company, Pharmaceuticals, Biotechnology, Life Sciences, and Neuroscience.

🌐 Visit website 📡 Source on GitHub

5.8/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-25 · rubric v0.14.0

0 APIs

Company Pharmaceuticals Biotechnology Life Sciences Neuroscience Mental Health Clinical Trials Drug Discovery Health

Kin Score

Kin Score How this is scored →
scored 2026-08-25 · rubric v0.14.0

Composite quality — 5.8/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Access Clarity 1.8 / 17

Operational Transparency 0.0 / 11

Contract Governance 0.0 / 10

Discoverability 3.9 / 9

Regulatory Posture 1.9 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Delegated User Identity 0 / 6

Protected Resource Metadata 0 / 5

Registration Without a Human 0 / 6

Agentic Commerce Surface 0 / 5

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/gilgamesh-pharma: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

Company 3

The organization behind the API

Website

Website

LinkedIn

Twitter

Twitter

Other 1

Properties that don't map to a standard resource type

Listing

Listing

Source (apis.yml)

aid: gilgamesh-pharma
name: Gilgamesh Pharma
description: 'Gilgamesh Pharma (Gilgamesh Pharmaceuticals, Inc.) is a New York based clinical-stage neuroscience company founded
  in 2019 that develops rapid-acting, next-generation therapeutics for psychiatric and substance use disorders. Its discovery
  and translational platform combines medicinal chemistry, neurocircuitry science, electrophysiology and machine learning
  to identify new chemical entities, and its pipeline spans short-acting 5-HT2A receptor agonists, NMDA receptor antagonists,
  non-hallucinogenic neuroplastogens, cardiac-safe ibogaine analogs and M1/M4 muscarinic programs. Lead assets include bretisilocin
  (GM-2505), acquired by AbbVie in August 2025, and blixeprodil (GM-1020), an orally bioavailable NMDAR antagonist in Phase
  2 for major depressive disorder. Gilgamesh is a drug developer, not a software vendor: it publishes no developer program,
  public API, SDK or machine-readable specification of any kind.'
url: https://raw.githubusercontent.com/api-evangelist/gilgamesh-pharma/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-21'
modified: '2026-08-21'
tags:
- Company
- Pharmaceuticals
- Biotechnology
- Life Sciences
- Neuroscience
- Mental Health
- Clinical Trials
- Drug Discovery
- Health
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/gilgamesh-pharma-domain-security.yml
- type: Website
  url: https://www.gilgameshpharmaceutical.com/
- type: LinkedIn
  url: https://www.linkedin.com/company/gilgamesh-pharmaceuticals/
- type: Twitter
  url: https://twitter.com/gilgameshrx
- type: PrivacyPolicy
  url: https://mcusercontent.com/6c3f21fb747d330b7d588cc87/files/e79eefcc-bae9-6748-dc85-17d889fdb1af/Gilgamesh_Privacy_and_Expanded_Access_Policy_08.14.26.pdf
- type: Listing
  url: https://forgeglobal.com/gilgamesh-pharma_stock/
x-enrichment:
  date: '2026-08-21'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Gilgamesh Pharma is a clinical-stage drug developer whose entire web presence is a single static marketing page
    on tiiny.host; /developers, /api, /docs, /openapi.json, /graphql, /llms.txt and every /.well-known/ path all return the
    site's own 404, and the company ships molecules (bretisilocin, blixeprodil) rather than software, so there is no API to
    publish.
  evidence:
  - url: https://www.gilgameshpharmaceutical.com/
    status: 200
  - url: https://www.gilgameshpharmaceutical.com/developers
    status: 404
  - url: https://www.gilgameshpharmaceutical.com/openapi.json
    status: 404
  - url: https://www.gilgameshpharmaceutical.com/.well-known/agent-card.json
    status: 404
  checked: '2026-08-21'

Work with this as data

Every provider here is available over the APIs.io API and to AI agents over MCP.

MCP server

One button, every client — Claude, Cursor, VS Code and the rest.

https://apis.io/mcp

Tools for providers

9 MCP tools reach this

find_providersBrowse and filter every provider in the catalog.
get_provider_artifactsEvery artifact this provider publishes, grouped by type.
get_provider_operationsEvery operation across all of their OpenAPIs — one call instead of parsing every spec.
get_provider_toolsEvery MCP tool they ship, with the operation each wraps.
get_provider_evidenceHow each part of their score was established. Free — the basis for a claim should not sit behind it.
get_provider_ratingPRO — composite, band, trend and facet scores.
apis_io_searchSTART HERE — APIs, providers and tags for one query, each with its total.
resolveTurn a domain, URL or GitHub org into the provider it belongs to.
find_cohortsEvery scored population of providers in the catalog.

All 92 tools

Call it yourself

curl for this page

This provider

curl "https://apis.io/api/v1/providers/gilgamesh-pharma"

All providers

curl "https://apis.io/api/v1/providers?limit=25"

Every operation they expose

curl "https://apis.io/api/v1/providers/gilgamesh-pharma/operations?limit=25"

How their score was established

curl "https://apis.io/api/v1/providers/gilgamesh-pharma/evidence"

Discovery needs no key. Ratings and market analysis are Pro.

Get an API key

Free tier, no email required.

GitHub Google LinkedIn

A second provider on the same verified email joins the account you already have.